Diversified Trust Co Sells 1,218 Shares of Danaher Co. (NYSE:DHR)

Diversified Trust Co trimmed its position in shares of Danaher Co. (NYSE:DHRGet Rating) by 44.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,546 shares of the conglomerate’s stock after selling 1,218 shares during the quarter. Diversified Trust Co’s holdings in Danaher were worth $392,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Danaher by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 51,004,840 shares of the conglomerate’s stock valued at $14,961,250,000 after acquiring an additional 1,044,650 shares in the last quarter. Norges Bank bought a new stake in Danaher in the 4th quarter valued at $2,015,889,000. Parnassus Investments LLC lifted its position in Danaher by 1.2% in the 1st quarter. Parnassus Investments LLC now owns 4,487,356 shares of the conglomerate’s stock valued at $1,316,276,000 after acquiring an additional 55,114 shares in the last quarter. Fisher Asset Management LLC lifted its position in Danaher by 3.7% in the 1st quarter. Fisher Asset Management LLC now owns 3,745,126 shares of the conglomerate’s stock valued at $1,098,558,000 after acquiring an additional 132,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Danaher by 3.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,260,664 shares of the conglomerate’s stock valued at $956,451,000 after acquiring an additional 108,414 shares in the last quarter. 77.27% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on DHR shares. Credit Suisse Group started coverage on shares of Danaher in a research report on Wednesday, August 24th. They set an “outperform” rating and a $340.00 price target on the stock. UBS Group boosted their price target on shares of Danaher from $297.00 to $323.00 and gave the stock a “buy” rating in a research report on Thursday, July 28th. Barclays boosted their price target on shares of Danaher from $290.00 to $310.00 in a research report on Friday, July 22nd. Sanford C. Bernstein started coverage on shares of Danaher in a research report on Tuesday, August 16th. They set an “outperform” rating and a $340.00 price target on the stock. Finally, Robert W. Baird boosted their price target on shares of Danaher from $319.00 to $325.00 in a research report on Friday, July 22nd. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $321.75.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 25,000 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $300.00, for a total value of $7,500,000.00. Following the transaction, the chief executive officer now directly owns 79,739 shares of the company’s stock, valued at approximately $23,921,700. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Danaher news, EVP Joakim Weidemanis sold 12,000 shares of the company’s stock in a transaction on Monday, July 25th. The stock was sold at an average price of $271.13, for a total value of $3,253,560.00. Following the transaction, the executive vice president now directly owns 74,398 shares of the company’s stock, valued at approximately $20,171,529.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Rainer Blair sold 25,000 shares of the company’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $300.00, for a total value of $7,500,000.00. Following the completion of the transaction, the chief executive officer now directly owns 79,739 shares in the company, valued at $23,921,700. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,906 shares of company stock valued at $11,823,179. 11.20% of the stock is owned by insiders.

Danaher Stock Down 0.8 %

DHR stock opened at $266.43 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $193.81 billion, a PE ratio of 31.38, a PEG ratio of 1.32 and a beta of 0.88. Danaher Co. has a 1-year low of $233.71 and a 1-year high of $331.68. The business’s 50 day simple moving average is $280.99 and its 200 day simple moving average is $269.91.

Danaher (NYSE:DHRGet Rating) last posted its earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share for the quarter, topping analysts’ consensus estimates of $2.35 by $0.41. The business had revenue of $7.75 billion for the quarter, compared to analyst estimates of $7.29 billion. Danaher had a return on equity of 18.57% and a net margin of 20.61%. The firm’s revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.46 EPS. As a group, research analysts anticipate that Danaher Co. will post 10.4 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 30th will be issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date is Thursday, September 29th. Danaher’s payout ratio is presently 11.78%.

Danaher Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

See Also

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.